Teva upgraded to Neutral from Sell at Goldman Goldman upgraded Teva to Neutral from Sell citing expectations that the narrative surrounding the company will now focus on growth and optionality in its underlying business. The firm raised its price target on shares to $52 from $40 and removed the stock from the Americas Sell List.
Teva board authorizes increase in share repurchase program to $3B The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.